

This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

THE NOMINATION COMMITTEE'S PROPOSAL

The Nomination Committee in Olink Holding AB (the "Company") proposes that the Annual General Meeting to be held April 7 2022 resolves as follows:

Item 2 Election of Chairman to preside over the Meeting

The Chairman of the Board, Jon Hindar, is proposed as Chairman to preside over the Meeting.

Item 11 Determination of the number of board members

The Nomination Committee proposes that the Board of Directors shall consist of nine board members and one deputy board member.

Item 12 Determination of fees for the Board of Directors and the Auditor

The fee for each Board member shall be as follows: USD 120,000 to the Chairman of the Board of Directors, USD 70,000 to each of the other Board members appointed by the Annual General Meeting who are not employed by the Company, additionally USD 20,000 to the Chairman of the Remuneration Committee and additionally USD 10,000 to each other member of the Remuneration Committee, additionally USD 30,000 to the Chairman of the Audit Committee and additionally USD 15,000 to each other member of the Audit Committee. If Tommi Unkuri is elected by the Annual General Meeting, he shall not receive any fees for Board or committee work. Total fees amount to USD 640,000.

Audit fees will be paid according to approved invoices.

Item 13 Election of board members and Chairman of the Board of Directors

Re-election of the Board members Jon Hindar, Jon Heimer, Solange Bullukian, Johan Lund, Nicolas Roelofs, Gustavo Salem and Tommi Unkuri and re-election of Johan Pietilä Holmner as deputy board member. Tina Nova have requested not to be re-elected.

Robert Schueren and Mary Reumuth are proposed as new board members.

Jon Hindar is proposed to be re-elected as Chairman of the Board of Directors.

Item 14 Election of Auditor

The Nomination Committee proposes, in accordance with the recommendation by the Audit Committee that has been approved by the whole Board as a recommendation, that registered auditing firm Ernst & Young AB be elected as auditor of the Company until the conclusion of the 2023 Annual General Meeting. Ernst & Young AB has notified that if the Annual General Meeting approves the proposal, authorized public accountant Fredrik Norrman will be the Auditor in charge.

This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

Presentation of proposed Board members

Jon Hindar

Jon Hindar has served as Chairman of the Board of Directors of the Company since January 2021. Mr. Hindar has served as a Principal of Summa Equity AB since January 2017. From 2015 until 2017, Mr. Hindar served as Chairman of the board of directors of Argentum Fondsinvesteringer AS, Hav Line AS and LGJ Invest AS. From March 2012 until June 2016, Mr. Hindar served as Chief Executive Officer of CermaqGroup AS. Mr. Hindar has served as Chairman of the board of directors of Arendals Fossekompagni ASA since June 2020, and also serves on the boards of multiple privately-held companies, including Milarex AS, Waterise AS and LGJ Invest AS. Mr. Hindar received his Master of Science and Engineering in chemistry from the Norwegian University of Science and Technology, and completed the Programme for Executive Development at IMD, Lausanne.

Jon Heimer

Jon Heimer has served as the Chairman of Olink Proteomics AB since 2014 and Chief Executive Officer of Olink Proteomics AB since January 2016 and has served as a member of the Board of Directors of the Company since December 2020. Prior to joining the Company, from April 2011 until December 2015, Mr. Heimer was a partner at Nexttobe AB, a family office/investment company focused on the Swedish biotechnology industry. Mr. Heimer has served as Chairman of the board of directors of Q-linea AB, and for multiple privately-held biotechnology companies, including Bioimics AB and Lumina Adhesives AB. Mr. Heimer is a serial entrepreneur, was one of the key persons in successful Q-Med starting off in the 1990's and has spent a large part of his professional career working from the United States in various investments and growth companies within the biotech space.

Solange Bullukian

Solange Bullukian has served as a member of the Board of Directors of the Company since January 2021. Ms. Bullukian is the Managing Principal of Scale2Growth which she founded in November 2017. Ms. Bullukian served as the Chief Financial Officer of Twist Bioscience Corporation. Previously, Ms. Bullukian has served as Chief Accounting Officer and prior to that as Chief Financial Officer of the Life Sciences Group at Agilent Technologies Inc. Ms. Bullukian is an Independent Director and Audit Committee Chair at Lumicks and has previously served on the Board of Directors of the European IRG Foundation for Agilent Technologies. Ms. Bullukian received her Master of Science in Management from the HEC (Ecole des Hautes Etudes Commerciales) School of Management in Paris, France.

Johan Lund

Johan Lund, PhD has served as a member of the Board of Directors of the Company since December 2020. He has served as the co-founder and Chief Executive Officer of KyNexis Medicine Development AB since August 2018. Since June 2018, Dr. Lund has also served as a consultant for MBS Pharma, which he founded. Prior to that, from March 2016 until May 2017, Dr. Lund served as Vice President and Head of the Immunology and Inflammation Therapeutic Center of Excellence of Celgene Corporation. From April 2015 until March 2016, Dr. Lund was Managing Partner at J. Lund and Associates, LLC, and from May 2015 until March 2016, Dr. Lund was a Senior Advisor for the Karolinska Institutet, advising on innovation and business creation as part of the European Institute for Innovation and Technology (EIT) Health Consortium. From August 2012 until March 2015, Dr. Lund served as Senior Vice President and Chief Scientific Officer of the Immunoscience Research Unit of Pfizer Inc. Dr. Lund has served as chairman of the board of directors for Aqilion AB since June 2018 and is a member of the board of directors of several privately-held companies, including Genagon Therapeutics AB and NEOGAP AB (formerly Tcer AB). Dr. Lund received his Med.Kand. degree and his Doctor of Medical Science degree from Karolinska Institutet. Dr. Lund also holds a diploma in

This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

Managing Medical Product Innovation from the Scandinavian International Management Institute in Copenhagen.

Nicolas Roelofs

Nicolas Roelofs has served as a member of the Board of Directors of the Company since December 2020. Dr. Roelofs has served as an Advising Partner of Summa Equity AB since July 2019. Dr. Roelofs has also served as Industrial Advisor of Nordic Capital since 2014. Dr. Roelofs serves as chairman of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., One BioMed Pte Ltd., ScaleBio Ltd., and Boreal Genomics Inc. Dr. Roelofs also serves as a member of the board of directors of multiple privately-held companies, including HyTest Ltd., The Binding Site Group Ltd., InSilixa, Inc., and LGC Group. He also serves as an advisory board member of 908 Devices Inc. Dr. Roelofs previously served as the President of the Life Sciences Group at Agilent Technologies, Group Operations Officer for the Life Sciences Division of Bio-Rad Inc., and Chief Operating Officer of Stratagene Inc. Dr. Roelofs received his Bachelor of Science in chemistry, biology, and German from Simpson College, his Master of Science in organic chemistry from Iowa State University, and his doctorate in organic chemistry from University of Nevada, Reno.

Gustavo Salem

Gustavo Salem has served as a member of the Board of Directors of the Company since March 2019 and was until December 2020 the Chairman of the Board of Directors. Mr. Salem has served as a Principle of Summa Equity AB since March 2020. Since its inception in January 2019, Mr. Salem has served as the co-founder and managing partner of Eureka Life Science LLC, which provides business strategy and commercialization support for innovative companies across the life sciences and diagnostics markets. From October 2016 through January 2019, Mr. Salem served as President of IDEX Health and Science and Group President of IDEX Corporation. From March 2015 until October 2016, Mr. Salem served as President of IDEX Health and Science, LLC and, from April 2014 until February 2015, served as President and Chief Executive Officer of SISCAPA Assay Technologies, Inc. Mr. Salem has served as the chairman of the board of directors of Liderança Group Inc. since August 2019 and also serves as a member of the board of directors of multiple privately-held companies, including SISCAPA Assay Technologies, Inc., IROA Technologies LLC and Sengenics Corporation Pte Ltd. Mr. Salem received his Bachelor of Arts in physiological psychology from University of California, Berkeley and was a Master of Science candidate in psychobiology at University of California, Irvine.

Tommi Unkuri

Tommi Unkuri has served as a member of the Board of Directors of the Company since March 2019. Mr. Unkuri has served as a Partner of Summa Equity AB since May 2016. From November 2015 until May 2016, Mr. Unkuri was a Partner at Fidelio Capital AB, and from April 2007 until December 2015, Mr. Unkuri worked with investments at Nordic Capital AB. Mr. Unkuri currently serves as a member of the board of directors of multiple privately-held companies, including Sengenics Corporation Pte Ltd., LOGEX Group and HyTest Ltd. Mr. Unkuri received his Master of Science from the Stockholm School of Economics.

Robert Schueren

Robert Schueren is an accomplished industry veteran with extensive molecular diagnostics, genomics, and pharma experience. Mr. Schueren has enjoyed an expansive 30-year career and has been a driving force behind rapid business growth at both start-up and large biotech companies. He currently serves as Chief Operating Officer of Natera, a publicly traded companies focused on Women's Health, Oncology and Organ Health diagnostics. Prior to that, he was CEO of IntegenX Inc., playing a critical role in the growth and success of the company, and ultimate acquisition by Thermo Fisher Scientific, as well as successfully leading a lobbying effort to pass the Rapid DNA Act of 2017. Mr. Schueren previously held executive leadership roles including GM of Genomics at Agilent

This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

Technologies, Global Head of Clinical Biomarkers and Operations, and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc. He formerly held leadership and commercial roles at Arcturus Bioscience, Accumetrics, Biosite Diagnostics, Gen-Probe, and Abbott Labs. Mr. Schueren received a BS in Pharmacy from Temple University.

Mary Reumuth

Mary Reumuth currently serves as the CFO at Kala Pharmaceuticals since July 2017. Ms. Reumuth joined Kala in 2014 as Corporate Controller. She has previously acted as an independent financial consultant from November 2012 to January 2014 and served as Corporate Controller for Enobia Pharma Corp., a biopharmaceutical company acquired by Alexion Pharmaceuticals, Inc., from May 2011 to June 2012. Ms. Reumuth has served as Director of Finance at Verenum Corporation, a biotechnology company, from December 2007 to March 2011. From 2001 to 2007, Ms. Reumuth held a variety of finance and accounting positions at Genzyme Corporation (acquired by Sanofi), and ILEX Oncology, Inc. Ms. Reumuth has served an auditor at Ernst & Young LLP. Ms. Reumuth earned her Bachelor's degree in Business Administration from Texas A&M University—Corpus Christi, and is a Certified Public Accountant.

Uppsala in March 2022

Olink Holding AB (publ)

The Nomination Committee in Olink Holding AB (publ)